
Dabur India Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what Dabur India management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Dabur India management said on order book — free account, 30 seconds.
Capex plans
Track Dabur India — get its next earnings analysis in your feed
How does Dabur India rank vs peers in Personal Products?
Pro featureHow does Dabur India rank in Personal Products?
Compare Dabur India against every Personal Products company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Dabur India's management said in earlier quarters
Others in Personal Products this season
- Anondita Medicare (Q2 FY27)
Revenue (Standalone)** for H1 FY27: ₹5,786.31 Lakhs, up 21.43% YoY from ₹4,765.06 Lakhs in H1 FY26 . Key investor presentation takeaways from Anondita Medicare
- Gillette India (Q2 FY27)
Revenue from operations for the quarter ended 30th September 2026: ₹84,610 lakh (Page 3) . Key results statement takeaways from Gillette India Ltd's Q2 FY27 ear
- Cupid (Q2 FY27)
Q2 FY27 revenue from operations: ₹187.86 Crores, up 122.5% YoY (Q2 FY26: ₹84.45 Crores) [Page 14, 16] . Key investor presentation takeaways from Cupid Ltd's Q2
- Honasa Consumer (Q2 FY27)
Younger brands, excluding The Derma Co., are growing healthily at 40%+ year-on-year, with the overall portfolio showing strong momentum across online and…